Axis-Shield gains Sangui CDT (carbohydrate deficient transferrin) line as firms settle:
This article was originally published in Clinica
Executive Summary
Sangui Biotech has agreed to stop selling its kits worldwide within 90 days after the company reached agreement with Anglo-Norwegian company Axis-Shield regarding alleged patent infringement on Axis' carbohydrate deficient transferrin (%CDT) assay. In addition, Sangui, of Santa Ana, California, is to sell to Upton, Cambridgeshire-based Axis its CDT business, used for the detection of excessive alcohol consumption, for $100,000.